vs

Side-by-side financial comparison of EAGLE FINANCIAL SERVICES INC (EFSI) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.

SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $16.4M, roughly 1.1× EAGLE FINANCIAL SERVICES INC). On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 21.3%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 1.5%).

Ally Financial Inc. is an American bank holding company incorporated in Delaware and headquartered at Ally Detroit Center in Detroit, Michigan. The company provides financial services including car finance, online banking via a direct bank, corporate lending, vehicle insurance, mortgage loans, and other related financing services such as installment sale and lease agreements.

SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.

EFSI vs SCYX — Head-to-Head

Bigger by revenue
SCYX
SCYX
1.1× larger
SCYX
$18.6M
$16.4M
EFSI
Growing faster (revenue YoY)
SCYX
SCYX
+1787.1% gap
SCYX
1808.5%
21.3%
EFSI
Faster 2-yr revenue CAGR
SCYX
SCYX
Annualised
SCYX
268.5%
1.5%
EFSI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EFSI
EFSI
SCYX
SCYX
Revenue
$16.4M
$18.6M
Net Profit
$12.3M
Gross Margin
Operating Margin
33.6%
56.3%
Net Margin
65.7%
Revenue YoY
21.3%
1808.5%
Net Profit YoY
376.5%
EPS (diluted)
$1.10
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EFSI
EFSI
SCYX
SCYX
Q4 25
$16.4M
$18.6M
Q3 25
$22.4M
$334.0K
Q2 25
$20.6M
$1.4M
Q1 25
$4.8M
$257.0K
Q4 24
$22.0M
$977.0K
Q3 24
$18.4M
$660.0K
Q2 24
$16.5M
$736.0K
Q1 24
$15.9M
$1.4M
Net Profit
EFSI
EFSI
SCYX
SCYX
Q4 25
$12.3M
Q3 25
$5.6M
$-8.6M
Q2 25
$5.3M
$-6.9M
Q1 25
$-7.0M
$-5.4M
Q4 24
Q3 24
$3.4M
$-2.8M
Q2 24
$3.2M
$-14.5M
Q1 24
$2.5M
$411.0K
Operating Margin
EFSI
EFSI
SCYX
SCYX
Q4 25
33.6%
56.3%
Q3 25
30.9%
-2516.5%
Q2 25
31.8%
-701.0%
Q1 25
-189.0%
-3350.2%
Q4 24
36.8%
Q3 24
21.6%
-1563.6%
Q2 24
22.9%
-1255.0%
Q1 24
19.1%
-692.5%
Net Margin
EFSI
EFSI
SCYX
SCYX
Q4 25
65.7%
Q3 25
25.0%
-2572.2%
Q2 25
25.6%
-504.8%
Q1 25
-145.8%
-2097.7%
Q4 24
Q3 24
18.6%
-425.5%
Q2 24
19.3%
-1964.4%
Q1 24
16.0%
29.9%
EPS (diluted)
EFSI
EFSI
SCYX
SCYX
Q4 25
$1.10
$0.25
Q3 25
$1.04
$-0.17
Q2 25
$0.98
$-0.14
Q1 25
$-1.53
$-0.11
Q4 24
$1.74
Q3 24
$0.97
$-0.06
Q2 24
$0.89
$-0.30
Q1 24
$0.72
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EFSI
EFSI
SCYX
SCYX
Cash + ST InvestmentsLiquidity on hand
$40.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$188.8M
$49.4M
Total Assets
$1.9B
$59.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EFSI
EFSI
SCYX
SCYX
Q4 25
$40.0M
Q3 25
$37.9M
Q2 25
$44.8M
Q1 25
$40.6M
Q4 24
$59.3M
Q3 24
$68.8M
Q2 24
$73.0M
Q1 24
$80.2M
Stockholders' Equity
EFSI
EFSI
SCYX
SCYX
Q4 25
$188.8M
$49.4M
Q3 25
$185.6M
$36.4M
Q2 25
$179.6M
$44.5M
Q1 25
$176.5M
$50.5M
Q4 24
$119.0M
$55.1M
Q3 24
$117.8M
$58.5M
Q2 24
$111.1M
$60.4M
Q1 24
$107.7M
$74.1M
Total Assets
EFSI
EFSI
SCYX
SCYX
Q4 25
$1.9B
$59.0M
Q3 25
$1.9B
$51.1M
Q2 25
$2.0B
$60.7M
Q1 25
$1.9B
$67.9M
Q4 24
$1.9B
$90.6M
Q3 24
$1.9B
$99.0M
Q2 24
$1.8B
$107.8M
Q1 24
$1.8B
$118.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EFSI
EFSI
SCYX
SCYX
Operating Cash FlowLast quarter
$25.8M
$18.4M
Free Cash FlowOCF − Capex
$24.3M
FCF MarginFCF / Revenue
148.6%
Capex IntensityCapex / Revenue
8.6%
Cash ConversionOCF / Net Profit
1.50×
TTM Free Cash FlowTrailing 4 quarters
$39.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EFSI
EFSI
SCYX
SCYX
Q4 25
$25.8M
$18.4M
Q3 25
$8.2M
$-8.7M
Q2 25
$2.6M
$-7.5M
Q1 25
$5.8M
$-7.5M
Q4 24
$18.8M
$-24.0M
Q3 24
$7.5M
$765.0K
Q2 24
$-1.8M
$-10.9M
Q1 24
$6.8M
$-4.0M
Free Cash Flow
EFSI
EFSI
SCYX
SCYX
Q4 25
$24.3M
Q3 25
$7.8M
Q2 25
$2.3M
Q1 25
$5.3M
Q4 24
$17.7M
Q3 24
$7.3M
Q2 24
$-2.2M
Q1 24
$6.7M
FCF Margin
EFSI
EFSI
SCYX
SCYX
Q4 25
148.6%
Q3 25
35.0%
Q2 25
11.2%
Q1 25
110.1%
Q4 24
80.6%
Q3 24
39.6%
Q2 24
-13.6%
Q1 24
41.9%
Capex Intensity
EFSI
EFSI
SCYX
SCYX
Q4 25
8.6%
Q3 25
1.7%
Q2 25
1.3%
Q1 25
11.2%
Q4 24
4.6%
Q3 24
1.3%
Q2 24
2.6%
Q1 24
0.6%
Cash Conversion
EFSI
EFSI
SCYX
SCYX
Q4 25
1.50×
Q3 25
1.47×
Q2 25
0.49×
Q1 25
Q4 24
Q3 24
2.19×
Q2 24
-0.57×
Q1 24
2.65×
-9.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EFSI
EFSI

Asset Management$6.0M37%
Other$3.8M23%
Interchange Fees$3.5M22%
Overdrawn Account Fees$1.6M10%
Brokerage Commissions$1.4M9%

SCYX
SCYX

Glaxosmithkline Intellectual Property$17.2M92%
Products$1.4M8%

Related Comparisons